(S)-ML753286
Modify Date: 2025-08-27 11:21:38
(S)-ML753286 structure
|
Common Name | (S)-ML753286 | ||
|---|---|---|---|---|
| CAS Number | 1699720-85-8 | Molecular Weight | 355.43 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H25N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of (S)-ML753286BCRP-IN-1 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter. |
| Name | BCRP-IN-1 |
|---|
| Description | BCRP-IN-1 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.6 μM (BCRP efflux transporter)[1] |
| In Vivo | BCRP-IN-1 (Compound A) shows the potency and a potent pharmacokinetic (PK) profile in rats (lower clearance [1.54 L/h/kg] and higher bioavailability [123%]). XL388 has moderate terminal elimination half-life with t1/2s of 0.9 h and 2.0 h for 2 mg/kg (iv) and 20 mg/kg (po) in rats, respectively[1]. |
| Animal Admin | Mice[1] To determine pharmacokinetic profile of BCRP-IN-1 and Ko143 in vivo, Sprague-Dawley rats are administered 2.0 mg/kg or 20 mg/kg BCRP-IN-1 or 2.0 mg/kg or 50 mg/kg Ko143, formulated in 0.5% HPMC/0.2% Tween80, via iv or po, respectively. After administration of BCRP-IN-1 or Ko143, blood is obtained from all animals at predose and at 0.083, 0.25, 0.5, 1, 4, 8, and 24 h postdose. Approximately 200 μL of whole blood is collected from the jugular vein catheter of each animal into tubes containing the anticoagulant dipotassium ethylenediaminetetraacetic acid (K2EDTA) and is further processed into plasma at approximately 4°C[1]. |
| References |
| Molecular Formula | C20H25N3O3 |
|---|---|
| Molecular Weight | 355.43 |
| Storage condition | 2-8℃ |